Edition:
United States

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

15.20USD
8 Dec 2016
Change (% chg)

-- (--)
Prev Close
$15.20
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
135,251
52-wk High
$18.75
52-wk Low
$9.61

Latest Key Developments (Source: Significant Developments)

Sucampo reports Q2 GAAP loss per share $0.02
Wednesday, 3 Aug 2016 06:30am EDT 

Sucampo Pharmaceuticals Inc : Q2 GAAP loss per share $0.02 . Q2 adjusted earnings per share $0.23 . Q2 earnings per share view $0.22 -- Thomson Reuters I/B/E/S . Q2 revenue $52 million versus I/B/E/S view $48.6 million . Sees FY 2016 adjusted earnings per share $0.97 to $1.07 . Sees FY 2016 revenue $195 million to $205 million .FY2016 earnings per share view $1.01, revenue view $203.6 million -- Thomson Reuters I/B/E/S.  Full Article

Sucampo Pharmaceuticals Inc reports top-line data from phase 2a study of cobiprostone
Tuesday, 19 Apr 2016 07:00am EDT 

Sucampo Pharmaceuticals Inc:Reports top-line data from phase 2a study of cobiprostone in patients with PPI-refractory non-erosive reflux disease and symptomatic gastroesophageal reflux disease.Says trial did not meet its primary endpoints.Says intends to discontinue development of cobiprostone for PPI-refractory NERD/sGERD.  Full Article

Sucampo Pharmaceuticals Inc reiterates FY 2016 guidance
Tuesday, 8 Mar 2016 06:30am EST 

Sucampo Pharmaceuticals Inc:Reiterated its earnings guidance for FY 2016.Expects total revenue of $195.0 million to $205.0 million, adjusted net income of $45.0 million to $50.0 million, adjusted EPS of $0.97 to $1.07, and adjusted EBITDA of $100.0 million to $105.0 million.Says adjusted net income guidance excludes amortization of acquired intangibles of about $17.6 million and amortization of the remaining inventory step-up costs of about $8.9 million.  Full Article

Sucampo Pharmaceuticals Inc enters into exclusive collaboration deal with cancer prevention pharmaceuticals
Monday, 11 Jan 2016 06:45am EST 

Sucampo Pharmaceuticals Inc:Press release - Sucampo enters into exclusive option and collaboration agreement with cancer prevention pharmaceuticals for development of late-stage cpp-1x/sulindac combination for familial adenomatous polyposis.Says phase 3 study expected to be complete in 2018.Says under the terms of the agreement, Sucampo will invest $5.0 million in cpp in the form of a convertible note.Says in addition, Sucampo will pay cpp an option fee of up to $7.5 million, payable in two tranches.Says under terms of the license, Sucampo and cpp would share equally in profits from the sale of approved products.Sucampo pharmaceuticals-co would acquire an exclusive license to product and would be obligated to pay cpp an aggregate of $190 million.  Full Article

Sucampo Pharmaceuticals Inc confirms FY 2016 guidance
Thursday, 7 Jan 2016 07:00am EST 

Sucampo Pharmaceuticals Inc:Confirms its previous guidance for FY 2016 of total revenue of $195.0 million to $205.0 million, adjusted net income of $45.0 million to $50.0 million, adjusted EPS of $0.97 to $1.07, and adjusted EBITDA of $100.0 million to $105.0 million.Says adjusted net income guidance excludes amortization of acquired intangibles of about $17.6 million and amortization of the remaining inventory step-up costs of about $8.9 million.  Full Article

Sucampo Pharmaceuticals Inc CEO Peter Greenleaf appointed board chairman
Tuesday, 15 Dec 2015 04:15pm EST 

Sucampo Pharmaceuticals Inc:Says CEO Peter Greenleaf appointed board chairman.Peter Greenleaf succeeds Dan Getman.  Full Article

Sucampo Pharmaceuticals Inc reaffirms FY 2015 guidance; amends FY 2016 guidance
Wednesday, 4 Nov 2015 06:33am EST 

Sucampo Pharmaceuticals Inc:Sucampo reiterated FY 2015 GAAP net income to be in the range of $30.0 million to $35.0 million, or $0.65 to $0.75 per diluted share.Expects FY 2016 to achieve net income of $45.0 million to $50.0 million, earnings per share of $0.97 to $1.07, and adjusted EBITDA of $100.0 million to $105.0 million.In addition, Sucampo expects to achieve pre-tax operational synergies of approximately $11.4 million on an annualized basis in 2016.  Full Article

Sucampo Pharmaceuticals Inc closes $250 million credit facility
Thursday, 22 Oct 2015 07:30am EDT 

Sucampo Pharmaceuticals Inc:Says closing of a $250.0 million credit facility in connection with the financing of its acquisition of R-Tech Ueno.  Full Article

Sucampo Pharmaceuticals Inc gives FY 2016 guidance
Wednesday, 26 Aug 2015 07:00am EDT 

Sucampo Pharmaceuticals Inc:Says that assuming a successful completion of the acquisition for FY 2016, excluding amortization and debt costs related to the proposed transaction, the company expects to achieve FY 2016 net income of $55 million to $60 million.Sees FY 2016 earnings per share of $1.20 to $1.30.Sees FY 2016 adjusted EBITDA of $95 million to $100 million.  Full Article

Sucampo Pharmaceuticals launches tender offer to acquire R-Tech Ueno
Wednesday, 26 Aug 2015 06:17am EDT 

Sucampo Pharmaceuticals Inc:Acquisition Expected to be Immediately Accretive.Says offer for a total consideration of JPY33 billion, or approximately $278 million.Sucampo expects to achieve pre-tax operational synergies of approximately $5 mln on an annualized basis in 2016.Says acquisition expected to close in Q4 2015.Intends to finance deal of R-Tech Ueno Through A Term Loan Of $250 mln committed by Jefferies Finance Llc and cash on hand.Does not expect the acquisition to have a material impact on 2015 results given the expected timing of transaction close.Says Sucampo is expecting to acquire 56% of the outstanding shares of R-tech Ueno in the tender offer.Entered into deal with R-Tech Ueno's founders and related entity to buy remaining 44% of R-tech Ueno for JPY1,400 per share.  Full Article

BRIEF-Sucampo Q3 adjusted EPS $0.28

* Sucampo pharmaceuticals inc - company raises 2016 guidance and provides preliminary 2017 guidance